Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 10/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202253 | 0.81 | EGFR (0.39) | EGFR | |
| SCHEMBL18958985 | 0.80 | EGFR (0.44) | HTR2AHTR2CEGFRMTNR1AMTNR1B | |
| SCHEMBL17270075 | 0.79 | HTR2A (0.43) | HTR2AHTR2CEGFRMTNR1AMTNR1B | |
| SCHEMBL17270038 | 0.78 | HTR2A (0.42) | HTR2AHTR2CEGFRMTNR1AMTNR1B | |
| SCHEMBL17270039 | 0.78 | HTR2A (0.44) | HTR2AHTR2CEGFRMTNR1AMTNR1B | |
| SCHEMBL17261896 | 0.78 | HTR2A (0.42) | HTR2AHTR2CEGFRMTNR1AMTNR1B | |
| SCHEMBL17270034 | 0.77 | EGFR (0.42) | HTR2AHTR2CEGFR | |
| SCHEMBL18958991 | 0.77 | HTR2A (0.41) | HTR2AHTR2CEGFRMTNR1AMTNR1B | |
| SCHEMBL17261870 | 0.76 | HTR2A (0.46) | HTR2AHTR2CEGFRMTNR1AMTNR1B | |
| SCHEMBL12475277 | 0.76 | EGFR (0.46) | HTR2AHTR2CEGFRKCNH2MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053971-A1 | CRYSTAL FORM OF MONOMETHANESULFONATE OF DEUTERATED 3-(4,5-SUBSTITUTED AMINOPYRIMIDINE)PHENYL COMPOUND AND PREPARATION METHOD THEREFOR | NANJING CAREPHAR SHENGHUI PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3498708-B1 | DEUTERATED 3-(4,5-SUBSTITUTED PYRIMIDINAMINE) PHENYL DERIVATIVES AND APPLICATIONS THEREOF | NANJING CHUANGTE PHARMACEUTICAL TECH CO LTD (CN) | 2021-01-13 | — | — | EP | disclosed |
| US-10654851-B2 | Deuterated 3-(4,5-substituted aminopyrimidine)phenyl derivatives and use thereof | Nanjing Chuangte Pharmaceutical Technology Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| CN-106687457-B | Heteroaryl compounds for kinase inhibition | 阿里亚德医药股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| WO-2019174623-A1 | CRYSTAL FORM OF MONOMETHANESULFONATE OF DEUTERATED 3-(4,5-SUBSTITUTED AMINOPYRIMIDINE)PHENYL COMPOUND, AND PREPARATION METHOD THEREFOR | 南京创特医药科技有限公司 | 2019-09-19 | — | — | WO | disclosed |
| US-20190225610-A1 | DEUTERATED 3-(4,5-SUBSTITUTED AMINOPYRIMIDINE)PHENYL DERIVATIVES AND USE THEREOF | Nanjing Chuangte Pharmaceutical Technology Co., Ltd (CN) | 2019-07-25 | — | — | US | disclosed |
| EP-3498708-A1 | DEUTERATED 3-(4,5-SUBSTITUTED PYRIMIDINAMINE) PHENYL DERIVATIVES AND APPLICATIONS THEREOF | Nanjing Chuangte Pharmaceutical Technology Co., Ltd (CN) | 2019-06-19 | — | — | EP | disclosed |
| EP-3143015-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3143015-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| EP-3143015-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2016029839-A1 | (SUBSTITUTED PHENYL) (SUBSTITUTED PYRIMIDINE) AMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICATION USE | 四川海思科制药有限公司 | 2016-03-03 | — | — | WO | disclosed |
| WO-2015175632-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053971-A1 | CRYSTAL FORM OF MONOMETHANESULFONATE OF DEUTERATED 3-(4,5-SUBSTITUTED AMINOPYRIMIDINE)PHENYL COMPOUND AND PREPARATION METHOD THEREFOR | EGFR, WEE1, HDGF | HTR2A 4141/4885HTR2C 2369/4885EGFR 1/4885 |
| US-20190225610-A1 | DEUTERATED 3-(4,5-SUBSTITUTED AMINOPYRIMIDINE)PHENYL DERIVATIVES AND USE THEREOF | EGFR, ERBB2, ERBB4 | HTR2A 2865/4885HTR2C 1677/4885EGFR 1/4885 |
| US-10654851-B2 | Deuterated 3-(4,5-substituted aminopyrimidine)phenyl derivatives and use thereof | EGFR, ERBB2, ERBB4 | HTR2A 2865/4885HTR2C 1677/4885EGFR 1/4885 |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | HTR2A 1220/4885HTR2C 735/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.